Filgrastim is marketed under several brand names, including Neupogen (Amgen), Imumax (Abbott Laboratories), Grafeel (Dr. Reddy's Laboratories), Neukine (Intas Biopharmaceuticals), Emgrast (Emcure Pharmaceuticals), Religrast (Reliance Life Sciences), Zarzio (Sandoz), Nufil (Biocon) and others.
Dr. Moore is a noted oncologist and hematologist primarily known for being the Principal Investigator in the development of filgrastim, marketed by Amgen under the brand name of Neupogen.
•
In collaboration with Amgen, recombinant G-CSF (Neupogen) was developed and in 1987 the first clinical studies were begun at Memorial Sloan-Kettering in cancer patients and pediatric patients with a genetic form of neutropenia.